Xvivo Perfusion AB (LTS:0RKL) Cyclically Adjusted Revenue per Share: kr15.30 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKL Xvivo Perfusion AB LTS:0RKL
86 GF Score
Price kr264.40
GF Value kr398.11
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Cyclically Adjusted Revenue per Share?

Xvivo Perfusion AB LTS:0RKL +1.54% 86 Cyclically Adjusted Revenue per Share is kr15.30 as of Jun. 2026. GuruFocus rates LTS:0RKL with a GF Score™ of 86/100 and a GF Value™ of kr398.11 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Xvivo Perfusion AB's adjusted revenue per share for the three months ended in Jun. 2026 was kr7.582. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr15.30 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Xvivo Perfusion AB's average Cyclically Adjusted Revenue Growth Rate was 15.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Xvivo Perfusion AB was 19.90% per year. The lowest was 19.90% per year. And the median was 19.90% per year.

As of today (2026-08-01), Xvivo Perfusion AB's current stock price is kr264.40. Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr15.30. Xvivo Perfusion AB's Cyclically Adjusted PS Ratio of today is 17.28.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xvivo Perfusion AB was 48.21. The lowest was 12.05. And the median was 27.31.


Xvivo Perfusion AB  (LTS:0RKL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Xvivo Perfusion AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=264.40/15.30
=17.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xvivo Perfusion AB was 48.21. The lowest was 12.05. And the median was 27.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Related Terms


Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 8.32 10.10 12.25 13.98

Xvivo Perfusion AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.19 13.78 13.98 14.69 15.30

LTS:0RKL vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Cyclically Adjusted PS Ratio falls into.


LTS:0RKL
86GF Score
Xvivo Perfusion AB LTS:0RKL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xvivo Perfusion AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7.582/134.6100*134.6100
=7.582

Current CPI (Jun. 2026) = 134.6100.

Xvivo Perfusion AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.332 101.138 1.773
201612 1.647 102.022 2.173
201703 1.573 102.022 2.075
201706 1.417 102.752 1.856
201709 1.222 103.279 1.593
201712 1.574 103.793 2.041
201803 1.622 103.962 2.100
201806 1.747 104.875 2.242
201809 1.527 105.679 1.945
201812 2.212 105.912 2.811
201903 1.783 105.886 2.267
201906 2.100 106.742 2.648
201909 2.021 107.214 2.537
201912 2.336 107.766 2.918
202003 1.746 106.563 2.206
202006 1.143 107.498 1.431
202009 1.475 107.635 1.845
202012 2.095 108.296 2.604
202103 1.981 108.360 2.461
202106 2.036 108.928 2.516
202109 1.888 110.338 2.303
202112 2.939 112.486 3.517
202203 3.102 114.825 3.636
202206 3.195 118.384 3.633
202209 3.281 122.296 3.611
202212 4.445 126.365 4.735
202303 4.714 127.042 4.995
202306 5.175 129.407 5.383
202309 4.865 130.224 5.029
202312 4.944 131.912 5.045
202403 5.906 132.205 6.013
202406 6.653 132.716 6.748
202409 6.264 132.304 6.373
202412 7.190 132.987 7.278
202503 6.906 132.825 6.999
202506 5.650 133.699 5.689
202509 5.994 133.480 6.045
202512 7.166 133.390 7.232
202603 7.636 133.560 7.696
202606 7.582 134.610 7.582

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr15.30 mean?
Xvivo Perfusion AB (LTS:0RKL) has a Cyclically Adjusted Revenue per Share of kr15.30 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share too high?
Xvivo Perfusion AB's current Cyclically Adjusted Revenue per Share is kr15.30. Overall, Xvivo Perfusion AB has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share of kr15.30 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Cyclically Adjusted Revenue per Share is kr15.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (LTS:0RKL) is currently considered Significantly Undervalued. The stock's GF Value™ is kr398.11, compared to a current price of kr264.40 — trading 33.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr15.30. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Xvivo Perfusion AB (LTS:0RKL), the current Cyclically Adjusted Revenue per Share is kr15.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (LTS:0RKL) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of kr264.40 is trading 33.6% below its estimated GF Value™ of kr398.11. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for LTS:0RKL:

  • Cyclically Adjusted Revenue per Share: kr15.30
  • GF Value™: kr398.11 vs. price of kr264.40 (33.6% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RKL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score

Get the complete analysis for LTS:0RKL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr264.40
Price
kr398.11
GF Value